

FOR PUBLIC RELEASE
NZX Limited
Wellington

Thursday, 16 December 2021

Notice of Special Meeting

Rua Bioscience (NZX:RUA) is pleased to invite shareholders to a Special Meeting to vote on a resolution to issue new Rua shares to the vendor shareholders of Zalm Therapeutics Limited (**Zalm**) for the acquisition of Zalm, as announced to the market on 30 November 2021.

The virtual-only meeting will be held at <https://meetnow.global/nz> commencing at 12:00 noon on 19 January 2022.

The transaction is fully outlined in our Investor Presentation available at www.ruabio.com/zalm-transaction and at nzx.com/companies/RUA/announcements, which we encourage you to review.

Rua's Board and senior management believe the acquisition of Zalm presents an outstanding commercial opportunity that will significantly strengthen Rua's ability to deliver on its commitments to our patients, shareholders and community by diversifying revenue, speeding market entry and expanding patient choice.

You are warmly encouraged to attend the Special Meeting, ask questions and make your vote count. You will simply require your shareholder number, found on your proxy form for verification purposes. Details on how to participate online are set out in the attached Notice of Meeting.

Ends.

For more information, please contact:
Kerry Donovan
Communications Manager Rua Bioscience
Email: kerry.donovan@ruabio.com
Phone: 021 128 7689

New Zealand pharmaceutical company Rua Bioscience aims to be a leading producer of cannabinoid derived medicines. The company was established in 2017 to support local economic development in Te Tairāwhiti and is a forerunner in the New Zealand medicinal cannabis sector.

Rua has developed two commercial-scale facilities (a controlled cultivation site in Ruatorea and a manufacturing and extraction plant in Gisborne) and holds a New Zealand exclusive contract with German distributor Nimbus Health to supply dried flower to Germany. Rua also has a well-defined strategy to identify long-term value opportunities across the medicinal cannabis value chain.